Why is "Ad5-nCoV" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-26 22:37:21
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Ad5-nCoV entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-26 and was most recently seen on 2026-08-26.
Wikipedia Overview
AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial | npj Vaccines - Nature
-
The CanSino Biologics Ad5-nCoV-S [recombinant] COVID-19 vaccine: What you need to know - World Health Organization (WHO)
-
Efficacy, Safety of the Ad5-nCoV Vaccine for Protection Against COVID-19 - Infectious Disease Advisor
-
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial - The Lancet
-
China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data - Fierce Pharma
-
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial - Nature
-
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial - The Lancet
-
World’s First Covid Vaccine You Inhale Is Approved in China - Bloomberg
-
CanSino's coronavirus vaccine candidate approved for military use in China - CNBC
-
CanSino's COVID-19 vaccine candidate approved for military use in China - Reuters
-
Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China - Nature
-
WHO validates 11th vaccine for COVID-19 - World Health Organization (WHO)
-
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlle - The Lancet
-
Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization - Nature
-
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial - The Lancet
-
Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults - Nature
-
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial - The Lancet
-
Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine - Nature
-
Unravelling the enhanced vaccine immunity by heterologous KCONVAC/Ad5-nCoV COVID-19 vaccination - Nature
-
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge - Nature
-
China approves COVID-19 vaccine for military use as it enters clinical trials - upi.com
-
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial - The Lancet
-
China’s CanSino defends its coronavirus vaccine candidate - Al Jazeera
-
Single Dose of China’s Ad5-nCoV COVID-19 Vaccine Is Safe and Effective in Phase 3 Trial - SciTechDaily
-
China CanSinoBIO's vaccine 57.5% effective against COVID in Phase III trial-study - Reuters
-
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet
-
China is starting clinical trials of a Covid vaccine that can be inhaled - CNBC
-
China’s military approves coronavirus vaccine for its own use - Fortune
-
China grants 1st COVID-19 vaccine patent to domestic candidate - news.cgtn.com
-
China trials mixing of CanSinoBIO's and Zhifei Longcom's COVID-19 vaccines -data - Reuters
-
Mexico approves China's CanSino and Sinovac COVID-19 vaccines - Reuters
-
More evidence suggests no long-term COVID-19 immunity - Royal Australian College of General Practitioners (RACGP)
-
China approves COVID-19 vaccine for military use, skips final phase of testing - CBC
-
Malaysia's Solution Group to supply 3.5 mln doses of CanSino vaccine to government - Reuters
-
CEO of Chinese drugmaker defends his COVID vaccine’s January 2022 timeline - Fortune
-
China’s military is world’s first to use experimental coronavirus vaccine - South China Morning Post
-
Canadian COVID-19 clinical trial scrapped after China wouldn't ship potential vaccine - CBC
-
Global race for virus vaccine heats up as China seeks volunteers for trial - South China Morning Post
-
World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - BioSpace
-
Graphics: How soon can we get a COVID-19 vaccine? - news.cgtn.com
-
13 COVID-19 Vaccines Are in Human Clinical Trials – What Are They? - Technology Networks
-
CanSinoBIO Receives EU GMP Certificate: Company - 启明创投
-
China Has A Vaccine Candidate That Can Kill The Coronavirus In Humans - bgr.com
-
Chinese-made vaccine able to fight all mutations: developer - Global Times
-
Canada's first COVID-19 vaccine trials approved for Halifax university - CBC
-
CanSino Biologics and Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine - PR Newswire Canada
-
Studies provide glimpse at efficacy of Covid-19 vaccines from Oxford-AstraZeneca and CanSino - STAT
-
Canada yet to receive vaccine candidate from Chinese developer it reached an agreement with in May - iPolitics
-
Did diplomatic tensions scuttle China-Canada Covid-19 vaccine trial? - South China Morning Post
-
China's COVID-19 vaccine shows "no side effects" in Russian trials - Ecns.cn
-
[VACCINE UPDATE] Fourth Chinese Vaccine Enters Phase 3 Trials, Bringing Global Total to Seven - DongA Science
-
Inside the CanSino Phase 3 COVID-19 vaccine trial at Pakistan’s Shifa Hospital - Arab News
-
Pakistan to conduct phase-III clinical trial of Covid-19 vaccine - ET HealthWorld
-
Pakistani doctor urges people to volunteer for COVID-19 vaccine trial - Arab News PK
-
Covid-19 vaccine maker offers shares in China’s second costliest IPO - South China Morning Post
-
Chinese mRNA-based COVID vaccines effective in preclinical trials - Macau Business
-
Inside the CanSino Phase 3 COVID-19 vaccine trial at Pakistan’s Shifa Hospital - Arab News
-
Phase 3 trials of Covid vaccine to begin in Karachi’s Indus Hospital next week - The Express Tribune
-
AstraZeneca Covid-19 vaccine approved for emergency use in Pakistan - The Express Tribune
-
Inside the CanSino Phase 3 COVID-19 vaccine trial at Pakistan’s Shifa Hospital - Arab News
-
China’s army gives limited approval to potential Covid-19 vaccine - Modern Ghana
-
China giving experimental coronavirus vaccines to high-risk groups since July, says official - Gulf News
-
Inside the CanSino Phase 3 COVID-19 vaccine trial at Pakistan’s Shifa Hospital - Arab News PK
-
Solution Biologics-CanSino Partnership Adds Value In Covid-19 Vaccines For Malaysia and ASEAN - CodeBlue
-
Inside the CanSino Phase 3 COVID-19 vaccine trial at Pakistan’s Shifa Hospital - Arab News PK
-
COVID 19: WHO in collaboration with experts to speed up vaccine’s devt
| The New Times - The New Times
-
Solution Group unit inks deal with CanSino for vaccine distribution - The Malaysian Reserve
-
Scientists See Downsides to COVID-19 Vaccines from Russia, China - Tempo.co English
-
Pakistani doctor urges people to volunteer for COVID-19 vaccine trial - The Peninsula Qatar
-
Mild side effects of Covid-19 vaccines are normal: experts - The News International
-
China's first 1-dose Covid-19 vaccine rolls out; 500m people can be inoculated a year - The Star
-
Solution Group to procure Covid-19 vaccine from CanSino - NST Online
-
China’s CanSino in talks for Covid-19 vaccine Phase III trial overseas - Free Malaysia Today
-
CanSino's COVID-19 vaccine candidate approved for military use in China - Dunya News
-
DRAP approves licencing, marketing of CanSinoBIO vaccine - Profit by Pakistan Today
-
Pakistan to Begin CanSinoBio Vaccine’s Local Production Next Month - ProPakistani
-
Interview: What is happening with the CanSinoBIO vaccine in Pakistan? - thecorrespondent.pk
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.